Healthcare stocks:There has been huge investment in the health care sector from the Mutual Fund (MF) side in the month of June as well. Significantly, since the last several months, Mutual Funds are investing a lot in the health care sector. Earlier in the month of May also, mutual funds had invested heavily in this sector. According to the monthly data from MK Alternatives and Quantitative Research, mutual funds invested Rs 1,900 crore in the sector in May. The health care sector accounted for the largest share of mutual fund inflows in May.
Health care accounted for the largest share of total MF investment in June
Such is the interest in the sector that 10 of the 11 mutual fund houses covered by Nuwama Alternative & Quantitative Research have a higher focus on pharma and healthcare than their weightage in the Nifty 200. Nuwama’s report shows that the weightage of pharma and healthcare in the Nifty 200 index is 4.88 per cent. While 10 MF houses had allocated 4.97 per cent to 10.67 per cent of their total allocation to the sector till June.
Small and mid-cap companies saw the fastest growth in June
If we look at the very large pharma and healthcare sector, it is known that in June, the maximum growth was seen in small and mid-cap companies. Krishna Institute of Medical Sciences (KIMS) MF investment of Rs 710 crore has taken place in June. This is the largest investment in a single company in the pharma and healthcare sector in the month of June. Alkem Laboratories Has been the second favorite of MFs with an investment of Rs 300 crore. anymore Aurobindo Pharma The number was In this, MF investment of Rs 260 crore has taken place in June. Driven by strong demand and industry leading margins KIMS There is a lot of enthusiasm in the market regarding this.
Market bullish on Ajanta Pharma and Aurobindo Pharma
Other than this Ajanta Pharma The market is bullish about. Significantly, Ajanta Pharma is a company that is almost completely based on the domestic market. Experts believe that double digit growth will be seen in the Indian pharma market. Ajanta Pharma has seen its benefits.
Aurobindo Pharma The market is also bullish about The company is the largest player in the US generics market. This is a sector in which signs of growth have started showing in recent times.
Apart from this, there has been vigorous buying by MFs in some more midcap stocks of the health care sector in June. According to Nuama’s report, in June from MF Dr Lal PathLabs 180 crores in Rs. biocon 170 crores in Fortis Health 160 crore in and Rs. Laurus Labs I have seen purchases worth Rs 120 crore. Talking about small-caps Vijaya Diagnostic 190 crores in Rs. Orchid Pharma 180 crores in Rs. Thyrocare Tech 130 crores in Advanced Enzyme Rs 60 crore has been purchased in India and Rs 60 crore in Granules India.
Sun Pharma remains favorite among large-caps
As far as large-caps are concerned, according to the report of Nuwama Alternative and Quantitative Research Sun Pharma Has clearly emerged as a preferred stock of MFs. The stock featured in the top 10 holdings of four MF houses, Aditya Birla Sun Life MF, HSBC MF, ICICI Prudential MF and Nippon India MF in June.
Sun Pharma is a favorite of analysts because of its strong specialty business. Apart from this, the market has also welcomed the company’s decision to increase research and development spending in FY24. With this, the company can see an increase in long-term growth prospects.